ICLR DEADLINE NOTICE: BFA Law Alerts ICON plc Investors that Lost Money to Contact the Firm by the April 11 Class Action Deadline
New York, New York-- (Newsfile Corp. - February 25, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against ICON plc (NASDAQ: ICLR) and certain ...
CROX DEADLINE NOTICE: BFA Law Alerts Crocs, Inc. Investors that Lost Money to Contact the Firm by the March 24 Class Action Deadline
New York, New York-- (Newsfile Corp. - February 25, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Crocs, Inc. (NASDAQ: CROX) and ...
PharmiWeb8h
Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
Regulatory ApprovalFormycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® 25.02.2025 / 06:30 CET/CESTThe issuer is solely ...
JD Supra19h
FDA Accepts U.S. Biologics License Application for AVT06, Alvotech and Teva’s Proposed Aflibercept Biosimilar
Alvotech and Teva Pharmaceuticals (“Teva”) announced that the U.S. Food and Drug Administration (FDA) has accepted for review ...
BioPharma Dive20h
Sanofi, Teva add to case for new bowel disease drug
Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.
Taiwan News1d
Progesterone Market to Exceed USD 1.15 Billion, Projected 13.3%+ CAGR Through 2030
Increasing Incidence of Endometrial and Breast Cancer: The rising number of cases of endometrial and breast cancers globally is a significant driver for the progesterone market. For instance, in the U ...
manilatimes3d
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn's disease
In the CD cohort of the RELIEVE UCCD study, 26% (450 mg dose) and 48% (900 mg dose) of patients treated with duvakitug achieved the primary endpoint of endoscopic response (SES-CD)* compared to 13% on ...
CAPLYTA’S Strong Market Adoption Propels Its Rise As A Leading Antipsychotic Therapy | Delveinsight
Intra-Cellular Therapies' CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar de ...
manilatimes4d
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
SELARSDI is approved for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and ...
Le Lézard4d
Teva and Alvotech Announce SELARSDItm (ustekinumab-aekn) Injection Now Available in the U.S.
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDItm for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination ...
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide
Pursuing the world's first-ever orally-dosed liraglutide KELOWNA, BC / / February 20, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW ...
Teva Pharmaceutical Industries Ltd: Putting Patients First: Why Europe Must Act to Protect Access To Medicines
New research by Teva Pharmaceuticals Europe shows that 46% of generic medicines from the EU Critical List of Medicines are supplied by only one provider. This ...